Journal article
Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study
Abstract
INTRODUCTION: XALIA assessed the safety and effectiveness of rivaroxaban for deep vein thrombosis (DVT) treatment in routine clinical practice. This substudy describes the clinical characteristics and outcomes of 'early switchers' - patients who received heparin or fondaparinux for >2-14days and/or a vitamin K antagonist (VKA) for 1-14days before switching to rivaroxaban.
MATERIALS AND METHODS: Patients with DVT (latterly with concomitant …
Authors
Turpie AGG; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Ageno W
Journal
Thrombosis Research, Vol. 155, , pp. 23–27
Publisher
Elsevier
Publication Date
7 2017
DOI
10.1016/j.thromres.2017.04.001
ISSN
0049-3848